Product Description
Bethanechol is FDA approved to treat postoperative urinary retention, postpartum urinary retention, and overflow incontinence caused by neurogenic atony of the bladder. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK560587/)
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Cyprus | India | Ireland | Israel | Italy | Korea | Luxembourg | New Zealand | Philippines | Switzerland | Taiwan | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/10/2026 |
News Article |
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences |
|
11/13/2025 |
News Article |
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update |
|
10/14/2025 |
News Article |
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings |
|
10/06/2025 |
News Article |
Alpha Cognition to Present Clinical Data at ASCP Annual Meeting |